肿瘤细胞治疗研究
英文原题:Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY (BIG 4-11) trial.
Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY (BIG 4-11) trial.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
N-的 STEPP 图未识别出明显从加用 P 中获益的亚群,N+的 STEPP 图未识别出需要降阶梯治疗的亚群。TILs 百分比似乎比临床复合风险评分更能预测 P 的治疗效果。
APHINITY试验显示,在曲妥珠单抗和化疗的基础上加用辅助帕妥珠单抗(P),与加用安慰剂(Pla)相比,可显著改善HER2+早期乳腺癌患者的IDFS,无论是在总体人群还是在淋巴结阳性(N+)队列中。我们探讨了加用P是否可使某些N-亚组人群获益,以及是否应考虑对某些N+亚组人群进行降阶梯治疗。
亚群治疗效果模式图(STEPP)是一种探索性图形方法,用于绘制由感兴趣协变量定义的重叠患者亚群的治疗效果估计值。我们使用STEPP来估计6年IDFS百分比的Kaplan-Meier差异(P减去Pla:Δ ± 标准误[SE]),包括总体和按淋巴结状态,针对由以下因素定义的重叠亚群:(1)临床复合风险评分,(2)TIL(肿瘤浸润淋巴细胞)(TILs)百分比,以及(3)人表皮生长因子受体2(HER2)FISH拷贝数。由于多重性,Δ至少达到三个SE才值得关注。
6年IDFS百分比的平均绝对增益总体为2.8 ± 0.9;N+为4.5 ± 1.2,N-为0.1 ± 1.1。增益最大的是中等临床复合风险患者(总体5.3 ± 1.9;N+ 6.9 ± 2.3;N- 4.0 ± 3.0)、TILs百分比最高者(总体6.3 ± 1.7;N+ 7.4 ± 2.4;N- 3.2 ± 1.7)以及中等HER2拷贝数者(总体2.8 ± 1.9;N+ 7.4 ± 2.5;N- -1.3 ± 1.9),但缺乏明确证据表明存在亚群治疗效应差异的模式。
Subpopulation Treatment Effect Pattern Plot (STEPP) is an exploratory, graphical method that plots estimates of treatment effect for overlapping patient subpopulations defined by a covariate of interest. We used STEPP to estimate Kaplan-Meier differences in 6-year IDFS percentages (P minus Pla: Δ ± standard error [SE]), both overall and by nodal status, for overlapping subpopulations defined by (1) a clinical composite risk score, (2) tumour infiltrating lymphocytes (TILs) percentage, and (3) human epidermal growth factor receptor 2 (HER2) FISH copy number. Because of multiplicity, a Δ of at least three SE is required to warrant attention.
The average absolute gains in 6-year IDFS percentages were 2.8 ± 0.9 overall; 4.5 ± 1.2 for N+ and 0.1 ± 1.1 for N-. Largest gains were for patients with intermediate clinical composite risk (5.3 ± 1.9 overall; 6.9 ± 2.3 N+; 4.0 ± 3.0 N-), highest TILs percentage (6.3 ± 1.7 overall; 7.4 ± 2.4 N+; 3.2 ± 1.7 N-), and intermediate HER2 copy number (2.8 ± 1.9 overall; 7.4 ± 2.5 N+; -1.3 ± 1.9 N-), but clear evidence indicating a pattern of differential subpopulation treatment effects was lacking.
STEPP plots for N- did not identify subpopulations clearly benefiting from adding P, and those for N+ did not identify subpopulations warranting de-escalation. TILs percentage appeared to be more predictive of P treatment effect than clinical composite risk score. TRIAL REGISTRATION: clinicaltrials.gov Identifier NCT01358877.
MEMBER ACCOUNT
登录成功会直接打开下一页。